Christopher Moy

1.9k total citations
17 papers, 618 citations indexed

About

Christopher Moy is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christopher Moy has authored 17 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christopher Moy's work include Cancer Genomics and Diagnostics (5 papers), Cancer-related Molecular Pathways (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Christopher Moy is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Cancer-related Molecular Pathways (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Christopher Moy collaborates with scholars based in United States, Belgium and United Kingdom. Christopher Moy's co-authors include Richard Wooster, Yan Degenhardt, Joel Greshock, Junping Jing, Elizabeth McNeil, Sylvie Laquerre, Suso Platero, Kurtis E. Bachman, Matthew V. Lorenzi and Aidan G. Gilmartin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Christopher Moy

16 papers receiving 610 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Moy United States 12 363 270 177 161 85 17 618
Katherine R. Singleton United States 11 497 1.4× 209 0.8× 190 1.1× 135 0.8× 46 0.5× 16 652
Raul Ayala United States 9 483 1.3× 356 1.3× 253 1.4× 124 0.8× 58 0.7× 18 830
Yi‐Hung Carol Tan United States 17 344 0.9× 255 0.9× 200 1.1× 90 0.6× 56 0.7× 32 705
Natsuko Nomura United States 13 275 0.8× 168 0.6× 157 0.9× 202 1.3× 46 0.5× 29 676
Grit S. Herter-Sprie United States 10 350 1.0× 307 1.1× 103 0.6× 137 0.9× 39 0.5× 14 680
Andrew M. Waters United States 9 425 1.2× 397 1.5× 88 0.5× 211 1.3× 67 0.8× 17 794
Rosalin Mishra United States 11 421 1.2× 345 1.3× 139 0.8× 81 0.5× 37 0.4× 20 724
Jenny Y. Xue United States 9 654 1.8× 311 1.2× 133 0.8× 111 0.7× 61 0.7× 16 824
Stina Mui Singel United States 11 336 0.9× 297 1.1× 197 1.1× 138 0.9× 77 0.9× 26 599
Karijn Floor Netherlands 10 400 1.1× 244 0.9× 179 1.0× 100 0.6× 37 0.4× 12 588

Countries citing papers authored by Christopher Moy

Since Specialization
Citations

This map shows the geographic impact of Christopher Moy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Moy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Moy more than expected).

Fields of papers citing papers by Christopher Moy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Moy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Moy. The network helps show where Christopher Moy may publish in the future.

Co-authorship network of co-authors of Christopher Moy

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Moy. A scholar is included among the top collaborators of Christopher Moy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Moy. Christopher Moy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Pillai, Rathi N., Suresh S. Ramalingam, Meena Thayu, et al.. (2020). Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). JTO Clinical and Research Reports. 2(2). 100104–100104. 11 indexed citations
2.
Zhang, Xu‐Chao, Jun Wang, Guoguang Shao, et al.. (2019). Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nature Communications. 10(1). 1772–1772. 145 indexed citations
3.
Beane, Jennifer, Sarah A. Mazzilli, Joshua D. Campbell, et al.. (2019). Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nature Communications. 10(1). 1856–1856. 57 indexed citations
4.
Santiago-Walker, Ademi, Christopher Moy, Yohann Loriot, et al.. (2019). Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC).. Journal of Clinical Oncology. 37(7_suppl). 420–420. 3 indexed citations
5.
Wu, Tongfei, Hillary J. Millar, Dana Gaffney, et al.. (2018). Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models. Cancer Research. 78(13_Supplement). 4859–4859. 21 indexed citations
6.
Karkera, Jayaprakash D., Dana Gaffney, Ademi Santiago-Walker, et al.. (2017). Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Molecular Cancer Therapeutics. 16(8). 1717–1726. 43 indexed citations
7.
Lim, Lee P., Jennifer Hernandez, Tristan Shaffer, et al.. (2016). Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting. Annals of Oncology. 27. vi401–vi401. 2 indexed citations
8.
Longo, Thomas A., Jennifer A. Freedman, Wiguins Etienne, et al.. (2016). Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. European Urology. 70(5). 714–717. 13 indexed citations
9.
Gaffney, Dana, et al.. (2014). Abstract 2408: Identification of R-Spondin fusions in various types of human cancer. Cancer Research. 74(19_Supplement). 2408–2408. 4 indexed citations
10.
Corcoran, Ryan B., Gerald S. Falchook, Jeffrey R. Infante, et al.. (2013). Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).. Journal of Clinical Oncology. 31(15_suppl). 3507–3507. 11 indexed citations
11.
Mayes, Patrick A., Yan Degenhardt, Andrew Wood, et al.. (2012). Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition. International Journal of Cancer. 132(3). 16 indexed citations
12.
Jing, Junping, Joel Greshock, Joanna D. Holbrook, et al.. (2011). Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212. Molecular Cancer Therapeutics. 11(3). 720–729. 96 indexed citations
13.
Moy, Christopher, Muhammad Usman Aziz, Joel Greshock, et al.. (2011). Mutation and copy number detection in human cancers using a custom genotyping assay. Genomics. 98(4). 296–301.
14.
Moy, Christopher, Catherine A. Oleykowski, Ramona Plant, et al.. (2011). High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916. Journal of Translational Medicine. 9(1). 110–110. 6 indexed citations
15.
Degenhardt, Yan, Joel Greshock, Sylvie Laquerre, et al.. (2010). Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability. Molecular Cancer Therapeutics. 9(7). 2079–2089. 73 indexed citations
16.
Greshock, Joel, Kurtis E. Bachman, Yan Degenhardt, et al.. (2010). Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Research. 70(9). 3677–3686. 100 indexed citations
17.
Mooso, Benjamin A., Anisha Madhav, Skyler B. Johnson, et al.. (2010). Androgen Receptor Regulation of Vitamin D Receptor in Response of Castration-Resistant Prostate Cancer Cells to 1 -Hydroxyvitamin D5: A Calcitriol Analog. Genes & Cancer. 1(9). 927–940. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katherine R. Singleton Breakdown of academic impact, for papers by Raul Ayala Breakdown of academic impact, for papers by Yi‐Hung Carol Tan Breakdown of academic impact, for papers by Natsuko Nomura Breakdown of academic impact, for papers by Grit S. Herter-Sprie Breakdown of academic impact, for papers by Andrew M. Waters Breakdown of academic impact, for papers by Rosalin Mishra Breakdown of academic impact, for papers by Jenny Y. Xue Breakdown of academic impact, for papers by Stina Mui Singel Breakdown of academic impact, for papers by Karijn Floor
Rankless by CCL
2026